Editas Medicine Prices Up to $319.4M Public Offering to Fund EDIT-401 Clinical Development

Editas Medicine priced an underwritten public offering on May 26, 2026, consisting of approximately 55.6 million shares at $2.25 per share, generating initial gross proceeds of approximately $125 million. The offering also includes Series A warrants with a strike price of $2.25/share and Series B warrants at $2.70/share — if fully exercised, total potential gross proceeds could reach up to $319.4 million. The capital raise is intended to fund clinical development of EDIT-401 (the CRISPR/base-editing program for cardiovascular disease; first-in-human studies planned H2 2026), advance the company's pre-IND programs, and extend the operating runway beyond the ~$280M in cash reported at end of Q1 2026. The offering was led by Jefferies, TD Cowen, and Leerink Partners. The share price at offering ($2.25) reflects the substantial decline from Editas' 2021 peak (~$100+/share) amid a challenging biotech environment, but the company pivoted away from its sickle cell CRISPR program (which was discontinued in 2024 due to competition from Casgevy and risto-cel) toward the potentially much larger cardiovascular CRISPR market — where EDIT-401's triple-lipid reduction data (≥90% LDL-C, Lp(a), ApoB in NHP) positions it as a potentially best-in-class cardiovascular gene editing therapy. The capital raise, alongside positive pre-IND feedback from the FDA disclosed the same day, signals Editas' commitment to advancing EDIT-401 to clinic in 2026.